INmune Bio (INMB) Competitors $7.92 -0.17 (-2.10%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. AVXL, ABUS, EOLS, KALV, ANAB, COGT, ABCL, TRVI, SION, and CDXCShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), Trevi Therapeutics (TRVI), Sionna Therapeutics (SION), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences AbCellera Biologics Trevi Therapeutics Sionna Therapeutics ChromaDex INmune Bio (NASDAQ:INMB) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the media favor INMB or AVXL? In the previous week, INmune Bio and INmune Bio both had 3 articles in the media. INmune Bio's average media sentiment score of 1.86 beat Anavex Life Sciences' score of 1.53 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Anavex Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals believe in INMB or AVXL? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 35.2% of INmune Bio shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, INMB or AVXL? INmune Bio has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Which has preferable earnings and valuation, INMB or AVXL? INmune Bio has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$50K3,640.67-$30.01M-$1.93-4.10Anavex Life SciencesN/AN/A-$43M-$0.55-14.95 Does the MarketBeat Community favor INMB or AVXL? Anavex Life Sciences received 298 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.60% of users gave INmune Bio an outperform vote while only 74.92% of users gave Anavex Life Sciences an outperform vote. CompanyUnderperformOutperformINmune BioOutperform Votes14476.60% Underperform Votes4423.40% Anavex Life SciencesOutperform Votes44274.92% Underperform Votes14825.08% Do analysts prefer INMB or AVXL? INmune Bio currently has a consensus price target of $22.80, suggesting a potential upside of 187.88%. Anavex Life Sciences has a consensus price target of $44.00, suggesting a potential upside of 435.28%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is INMB or AVXL more profitable? Anavex Life Sciences' return on equity of -37.50% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -117.48% -78.96% Anavex Life Sciences N/A -37.50%-34.08% SummaryINmune Bio beats Anavex Life Sciences on 8 of the 15 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.03M$3.12B$5.61B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-3.6332.8927.2619.97Price / Sales3,640.67466.19412.06157.64Price / CashN/A168.6838.2534.64Price / Book3.833.417.064.69Net Income-$30.01M-$72.35M$3.24B$248.14M7 Day Performance7.76%6.75%2.56%2.39%1 Month Performance3.66%17.19%8.75%6.06%1 Year Performance-9.49%-17.58%31.30%13.57% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio2.4254 of 5 stars$7.92-2.1%$22.80+187.9%-4.9%$182.03M$50K-3.6310News CoveragePositive NewsHigh Trading VolumeAVXLAnavex Life Sciences3.9179 of 5 stars$7.56+0.4%$44.00+482.0%+121.6%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.244 of 5 stars$3.36flat$5.50+63.7%+10.1%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.1057 of 5 stars$9.97+8.5%$23.75+138.2%-11.6%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals4.0627 of 5 stars$12.92+9.5%$24.83+92.2%+10.5%$642.33MN/A-3.55100Positive NewsInsider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.7644 of 5 stars$21.86-1.7%$40.38+84.7%-0.2%$642.25M$111.87M-3.60100COGTCogent Biosciences2.5061 of 5 stars$5.61+3.1%$14.57+159.7%-17.7%$638.73MN/A-2.2680Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.6413 of 5 stars$2.14+5.9%$8.33+289.4%-5.8%$638.63M$23.11M-3.51500Options VolumeTRVITrevi Therapeutics3.5014 of 5 stars$6.32-2.9%$18.63+194.7%+140.4%$631.32MN/A-14.3620Gap UpHigh Trading VolumeSIONSionna TherapeuticsN/A$13.97+2.0%$38.50+175.6%N/A$616.41MN/A0.0035CDXCChromaDex2.6104 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120 Related Companies and Tools Related Companies Anavex Life Sciences Competitors Arbutus Biopharma Competitors Evolus Competitors KalVista Pharmaceuticals Competitors AnaptysBio Competitors Cogent Biosciences Competitors AbCellera Biologics Competitors Trevi Therapeutics Competitors Sionna Therapeutics Competitors ChromaDex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INMB Stock Free INMB Stock Alerts